Our Research Programs

HMRI’s Preclinical Research program provides transgenic, gene targeting, and other related rodent-model services to investigators of HMRI and affiliated institutions. HMRI investigators rely on animal models for several pivotal studies funded by government agencies, including the NIH, the DOD, and the TRDRP (Tobacco-Related Disease Research Program, State of California). Preclinical research applications at HMRI include novel therapies for hemorrhagic shock, heart attacks, and heart failure; the pathophysiology and treatment of migraines and strokes; and the pathophysiologic effect of electronic cigarettes on the heart and lungs. HMRI studies also include the use of sophisticated genetically altered animal models that seek to understand the molecular pathways of heart attack and heart failure, the development of blood vessels in the developing brain and how abnormalities in this development could lead to mental illness. 

Preclinical research provides HMRI and affiliated investigators the opportunity to test novel therapies designed for the prevention and treatment of heart attack and stroke, Alzheimer’s disease, and migraine, as well as investigation into neurological development that is linked to the biological basis of mental illness. Many of HMRI and affiliates’ discoveries stem from basic and translational research initiated and conducted in our preclinical research facility. 

HMRI’s preclinical research program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. We adhere to the Animal Welfare Regulations CFR, Title 9, Chapter 1, Subchapter A, Parts 1, 2 and 3 and the NRC Guide for the Care and Use of Laboratory Animals, and we maintain an Animal Welfare Assurance through the NIH Office for Laboratory Animal Welfare (OLAW).